Charles River Deepens Ties with Lilly's AI-Powered TuneLab Platform
Eli Lilly's TuneLab announced a collaboration with Charles River Laboratories to offer standardized nonclinical testing services to AI/ML-enabled biotech companies using the TuneLab platform. The deal ties Charles River more closely into Lilly's Catalyze360 ecosystem.
In June 2026, Eli Lilly (ticker: LLY) announced a new collaboration between its TuneLab platform and Charles River Laboratories (ticker: CRL). Under the agreement, Charles River will provide standardized nonclinical testing services to biotech companies that use TuneLab's AI/ML-driven drug discovery platform.
Collaboration Details
The collaboration aims to integrate Charles River's standardized preclinical testing capabilities with the TuneLab platform, accelerating drug discovery for biotech startups. It also deepens Charles River's integration into Lilly's Catalyze360 ecosystem, a program designed to support life sciences startups.
Context
This move is part of Lilly's broader strategy to expand its AI-driven drug discovery ecosystem and make TuneLab more attractive to startups. By offering standardized testing services, Charles River could become a key partner in AI-enhanced preclinical research workflows.
What It Means for Investors
For Charles River investors, this collaboration could boost revenue through increased demand for nonclinical testing services. For Lilly investors, it strengthens TuneLab's position as a leading AI drug discovery platform. Financial terms of the deal have not been disclosed.
Frequently Asked Questions
Found this useful? Share it